Master your Energywith Insights from Energy Leadership, Physical Intelligence & Mindfulness
19 June 2024
Master your Energywith Insights from Energy Leadership, Physical Intelligence & Mindfulness
19 June 2024
Carine Punt | CEO, BunyaVax
With more than 15 years of experience in the field of R&D drug development and biotech, Carine Punt currently contributes as CEO to the strategic management and successes of BunyaVax and Rabian BV. It is her ambition to connect her veterinary background and human drug development experiences to support the development of vaccines and prophylaxis against emerging virus-related diseases of animals and humans. Starting her career as a doctor of veterinary medicine (DVM) and a few years in veterinary academics, new challenges and personal development opportunities came on her way at diverse pharmaceutical companies, focusing on toxicology and R&D development. Since 2019 she developed her entrepreneurial skills further as CEO and co-founder. As a practical, results-driven professional and team player, Carine enjoys turning challenges into opportunities.
BunyaVax
BunyaVax has developed a proprietary technology to attenuate bunyaviruses and uses these technologies to develop live attenuated vaccines that optimally combine efficacy with safety against neglected diseases of animals and humans. The technologies are also being used to develop diagnostic assays of unmatched specificity and sensitivity. BunyaVax prioritizes viral pathogens that affect animal and human health in developing countries.
The current focus of the company is on Rift Valley fever virus (RVFV), a mosquito-transmitted pathogen of ruminants and humans that can affect millions of animals and thousands of humans in single outbreaks. BunyaVax is leading the LARISSA project (www.larissa.online) that is funded and supported by the Coalition for Epidemic Preparedness Innovations (CEPI) (www.cepi.net), which aims to develop a human Rift Valley fever vaccine. In parallel, BunyaVax is developing a vaccine for veterinary use in collaboration with a world-leading animal health company. More information about RVFV and the technology used to develop human and veterinary vaccines is on our website www.Bunyavax.com.
BunyaVax
BunyaVax has developed a proprietary technology to attenuate bunyaviruses and uses these technologies to develop live attenuated vaccines that optimally combine efficacy with safety against neglected diseases of animals and humans. The technologies are also being used to develop diagnostic assays of unmatched specificity and sensitivity. BunyaVax prioritizes viral pathogens that affect animal and human health in developing countries.
The current focus of the company is on Rift Valley fever virus (RVFV), a mosquito-transmitted pathogen of ruminants and humans that can affect millions of animals and thousands of humans in single outbreaks. BunyaVax is leading the LARISSA project (www.larissa.online) that is funded and supported by the Coalition for Epidemic Preparedness Innovations (CEPI) (www.cepi.net), which aims to develop a human Rift Valley fever vaccine. In parallel, BunyaVax is developing a vaccine for veterinary use in collaboration with a world-leading animal health company. More information about RVFV and the technology used to develop human and veterinary vaccines is on our website www.Bunyavax.com.
| Powered by: Hyphen Projects BV | Connect with us | Join TOPX | |||
| Privacy Policy Terms & Conditions Chamber of Commerce: 32110979 VAT no: NL8184.34.491.B01 | | |
© Copyright 2020 by Hyphen Projects